Molecular testing is highly sensitive and can help avoid missed positives in the detection of Clostridium difficile infection versus traditional methods. The BD MAX™ Cdiff is a test for patients suspected of having CDI through the detection of the C. difficile toxin B gene (tcdB) from liquid or soft stool. The assay provides a highly accurate result in an actionable timeframe and requires limited hands-on time as compared to traditional methods.1
Visit bd.com for detailed information on BD MAX Cdiff (Cat. No. 443418).
Molecular testing provides a fast result (as compared to culture), which can aid in more effective infection control measures. The BD MAX™ MRSA XT Panel is a screening test for nasal carriage of MRSA aiding in transmission prevention and infection control. The assay provides comprehensive coverage of 11 sequences of the SCCmec-orfX right-extremity junction (MREJ) region plus identification of mecA drop-out mutants and detection of the newly-emerging mecC gene.2
Visit bd.com for detailed information on BD MAX MRSA XT (Cat. No. 443461).
Patients with a MRSA surgical site infection have up to 11 times higher rate of mortality.3 The BD MAX™ StaphSR Panel is a pre-surgical screening test for nasal carriage of Staphylococcus aureus or MRSA aiding in transmission prevention and infection control. The assay offers the same level of comprehensive coverage as the BD MAX MRSA XT assay, including detection of the 11 MREJ regions, mecA drop-out mutants and the newly emerging mecC gene.4
Visit bd.com for detailed information on BD MAX StaphSR (Cat. No. 443419).